{
  "abstract": "Background Drug-coated balloons (DCBs), modern treatment for de novo coronary artery lesions, deliver antiproliferative drugs to the vessel wall during inflation.Methods A prospective, all-comers database at Galway University Hospital recorded de novo lesions treated with Paclitaxel/ Sirolimus-DCBs between January 2021-March 2025. Data pertaining demographics, clinical presentation, and procedural characteristics were collected. Procedural outcomes were compared at index procedure (including; QCA analysed residual in-lesion stenosis >40%, and bailout stenting), and 30-day follow-up (including; cardiac death, and target lesion revascularisation). Statistical analysis performed using IBM SPSS.Findings In 82 patients, 94 de novo lesions treated, with 76.6% (lesions=72) receiving Paclitaxel. Mean age 66.8 years (SD 11.53); 86.5% male. Obesity (BMI >30) was significantly higher in Paclitaxel (34%) versus Sirolimus (0%,p=0.013), whilst CKD (stage3/4) was less frequent in Paclitaxel (16.9%) versus Sirolimus (33.4%, p=0.078). There was a non-significant trend toward greater Paclitaxel use in acute coronary syndrome (Paclitaxel 58.3% vs. Sirolimus 40.9%) , vessels >3mm (Paclitaxel 30.6% vs. Sirolimus 9%), bifurcations (Paclitaxel 18.1% vs. Sirolimus 4.5%), and long lesions >30mm (Paclitaxel 12.5% vs. Sirolimus 4.5%) compared to Sirolimus (p>.05 for all comparisons) ( figure 1). Lesion preparation was similar between groups. Intracoronary imaging was used less frequently with Paclitaxel (8.3%) versus Sirolimus (54.4%, p <0.001).There was a non-significant trend towards lower percentage residual in-lesion stenosis (>40% by QCA measurement) with Paclitaxel versus Sirolimus (respectively 33.3% vs. 54.5%, p <.085) (figure 2). At 30-days, one Paclitaxel-DCB cardiac death occurred from decompensated heart failure; no target lesion revascularisations were reported.Abstract 75 Figure 1Abstract 75 Figure 2Interpretation Although Paclitaxel-DCBs were more frequently used in acute cases, complex lesions, and larger vessels, procedural outcomes and 30-day safety were similar to Sirolimus-DCBs. In a real-world setting, DCB for de novo lesions appears feasible and safe, even in complex cases, using a ‘leave-nothing-behind’ strategy.",
  "authors": [
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "T Muller"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "E Bianchini"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "B Hynes"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "D Mylotte"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "F Sharif"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "B MacNeill"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "J Crowley"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "P Nash"
    },
    {
      "affiliations": [
        "Galway University Hospital, Galway, Ireland"
      ],
      "name": "A McInerney"
    }
  ],
  "title": "75 Comparison of procedural outcomes between sirolimus- and paclitaxel-drug-coated balloons in de novo coronary lesion angioplasty at index procedure and at 30-day follow-up",
  "uid": "733c9bfe-dfbb-5f39-a307-4f88953dcfe2"
}